Melatonin protects SK-N-SH neuroblastoma cells from amphetamine-induced neurotoxicity

Journal of Pineal Research

Volumn 43, Issue 1, 2007, Pages 65-73

  Klongpanichapak, Sirirat ^a   Phansuwan Pujito, Pansiri ^b   Ebadi, Manuchair ^c   Govitrapong, Piyarat ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b SRINAKHARINWIROT UNIVERSITY   (Thailand)

^c UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

Amphetamine; Dopamine; Melatonin; Neurodegenerative disorder; Oxidative stress; Parkinson's disease; SK N SH cells

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA SYNUCLEIN; AMPHETAMINE; MALONALDEHYDE; MELATONIN; REACTIVE OXYGEN METABOLITE;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; HUMAN; HUMAN CELL; INTRACELLULAR SPACE; NEUROBLASTOMA CELL; NEUROPROTECTION; NEUROTOXICITY; OXIDATIVE STRESS; PROTEIN EXPRESSION; UPREGULATION;

CELL LINE, TUMOR; DEXTROAMPHETAMINE; HUMANS; MELATONIN; NEUROBLASTOMA; NEURONS;

EID: 34447118322     PISSN: 07423098     EISSN: 1600079X     Source Type: Journal    
DOI: 10.1111/j.1600-079X.2007.00444.x     Document Type: Article

References (58)

1. Ali SF, Newport GD, Holson RR et al. Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice. Brain Res 1994 658 : 33 38.
2. Itzhak Y, Ali SF. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo. J Neurochem 1996 67 : 1770 1773.
3. Hotchkiss AJ, Gibb JW. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 1980 214 : 257 262.
4. Wilson JM, Kalasinsky KS, Levey AI et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996 2 : 699 703.
5. Guilarte TR. Is methamphetamine abuse a risk factor in parkinsonism? Neurotoxicology 2001 22 : 725 731.
6. Ebadi M, Srinivasan SK, Baxi MD. Oxidative stress and antioxidant therapy in Parkinson's disease. Prog Neurobiol 1996 48 : 1 19.
7. Bove J, Prou D, Perier C et al. Toxin-induced models of Parkinson's disease. NeuroRx 2005 2 : 484 494.
8. Santamaria A, Salvatierra-Sanchez R, Vazquez-Roman B et al. Protective effects of the antioxidant selenium on quinolinic acid-induced neurotoxicity in rats: in vitro and in vivo studies. J Neurochem 2003 86 : 479 488.
9. Levi MS, Brimble MA. A review of neuroprotective agents. Curr Med Chem 2004 11 : 2383 2397.
10. Tan DX, Chen LD, Poeggeler B et al. Melatonin: a potent endogenous hydroxyl radical scavenger. Endocr J 1993 1 : 57 60.
11. Reiter RJ. Melatonin: lowering the high price of free radicals. News Physiol Sci 2000 15 : 246 250.
12. Rosen J, Than NN, Koch D et al. Interactions of melatonin and its metabolites with the ABTS cation radical: extension of the radical scavenger cascade and formation of a novel class of oxidation products, C2-substituted 3-indolinones. J Pineal Res 2006 41 : 374 381.
13. Tan DX, Manchester LC, Terron MP et al. One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 2007 42 : 28 42.
14. Rodriguez C, Mayo JC, Sainz RM et al. Regulation of antioxidant enzymes: a significant role for melatonin. J Pineal Res 2004 36 : 1 9.
15. Tomas-Zapico C, Coto-Montes A. A proposed mechanism to explain the stimulatory effect of melatonin on antioxidative enzymes. J Pineal Res 2005 39 : 99 104.
16. Martin M, Macias M, Escames G et al. Melatonin-induced increased activity of the respiratory chain complexes I and IV can prevent mitochondrial damage induced by ruthenium red in vivo. J Pineal Res 2000 28 : 242 248.
17. Acuna-Castroviejo D, Martin M, Macias M et al. Melatonin, mitochondria, and cellular bioenergetics. J Pineal Res 2001 30 : 65 74.
18. Martin M, Macias M, Leon J et al. Melatonin increases the activity of the oxidative phosphorylation enzymes and the production of ATP in rat brain and liver mitochondria. Int J Biochem Cell Biol 2002 34 : 348 357.
19. Acuna-Castroviejo D, Escames G, Leon J et al. Mitochondrial regulation by melatonin and its metabolites. Adv Exp Med Biol 2003 527 : 549 557.
20. Leon J, Acuna-Castroviejo D, Sainz RM et al. Melatonin and mitochondrial function. Life Sci 2004 75 : 765 790.
21. Leon J, Acuna-Castroviejo D, Escames G et al. Melatonin mitigates mitochondrial malfunction. J Pineal Res 2005 38 : 1 9.
22. Ajjimaporn A, Swinscoe J, Shavali S et al. Metallothionein provides zinc-mediated protective effects against methamphetamine toxicity in SK-N-SH cells. Brain Res Bull 2005 67 : 466 475.
23. Klongpanichapak S, Govitrapong P, Sharma SK et al. Attenuation of cocaine and methamphetamine neurotoxicity by coenzyme Q10. Neurochem Res 2006 31 : 303 311.
24. Poeggeler B, Thuermann S, Dose A et al. Melatonin's unique radical scavenging properties - roles of its functional substituents as revealed by a comparison with its structural analogs. J Pineal Res 2002 33 : 20 30.
25. Hardeland R, Pandi-Perumal SR. Melatonin, a potent agent in antioxidative defense: actions as a natural food constituent, gastrointestinal factor, drug and prodrug. Nutr Metab (Lond) 2005 2 : 22.
26. Srinivasan V, Pandi-Perumal SR, Maestroni GJ et al. Role of melatonin in neurodegenerative diseases. Neurotoxicol Res 2005 7 : 293 318.
27. Fornai F, Lenzi P, Gesi M et al. Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J Neurochem 2004 88 : 114 123.
28. Quan L, Ishikawa T, Michiue T et al. Ubiquitin-immunoreactive structures in the midbrain of methamphetamine abusers. Leg Med (Tokyo) 2005 7 : 144 150.
29. Olanow CW, Tatton WG. Etiology and pathogenesis of Parkinson's disease. Annu Rev Neurosci 1999 22 : 123 144.
30. Cheng N, Maeda T, Kume T et al. Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons. Brain Res 1996 743 : 278 283.
31. Chetsawang B, Govitrapong P, Ebadi M. The neuroprotective effect of melatonin against the induction of c-Jun phosphorylation by 6-hydroxydopamine on SK-N-SH cells. Neurosci Lett 2004 371 : 205 208.
32. Ko L, Mehta ND, Farrer M et al. Sensitization of neuronal cells to oxidative stress with mutated human alpha-synuclein. J Neurochem 2000 75 : 2546 2554.
33. Tabrizi SJ, Orth M, Wilkinson JM et al. Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet 2000 9 : 2683 2689.
34. Lee FJ, Liu F, Pristupa ZB et al. Direct binding and functional coupling of alpha-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis. Faseb J 2001 15 : 916 926.
35. Tanaka Y, Engelender S, Igarashi S et al. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Hum Mol Genet 2001 10 : 919 926.
36. Xu J, Kao SY, Lee FJ et al. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med 2002 8 : 600 606.
37. Hashimoto M, Hsu LJ, Xia Y et al. Oxidative stress induces amyloid-like aggregate formation of NACP/alpha-synuclein in vitro. Neuroreport 1999 10 : 717 721.
38. Souza JM, Giasson BI, Chen Q et al. Dityrosine cross-linking promotes formation of stable alpha-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J Biol Chem 2000 275 : 18344 18349.
39. Vega-Naredo I, Poeggeler B, Sierra-Sanchez V et al. Melatonin neutralizes neurotoxicity induced by quinolinic acid in brain tissue culture. J Pineal Res 2005 39 : 266 275.
40. Hardeland R, Burkhardt S, Antolin I. Melatonin and 5-methoxytryptamine in the bioluminescent dinoflagellate Gonyaulax polyedra. In : Melatonin after Four Decades. Olcese J, ed. Kluwer Academic/Plenum Publishers, New York, 2000 pp. 387 390.
41. Reiter RJ, Tan DX, Pappolla MA. Melatonin relieves the neural oxidative burden that contributes to dementias. Ann N Y Acad Sci 2004 1035 : 179 196.
42. Sandyk R. Pineal melatonin functions: possible relevance to Parkinson's disease. Int J Neurosci 1990 50 : 37 53.
43. Mayo JC, Sainz RM, Tan DX et al. Melatonin and Parkinson's disease. Endocrine 2005 27 : 169 178.
44. Miller JW, Selhub J, Joseph JA. Oxidative damage caused by free radicals produced during catecholamine autoxidation: protective effects of O-methylation and melatonin. Free Radic Biol Med 1996 21 : 241 249.
45. Khaldy H, Escames G, Leon J et al. Comparative effects of melatonin, L-deprenyl, Trolox and ascorbate in the suppression of hydroxyl radical formation during dopamine autoxidation in vitro. J Pineal Res 2000 29 : 100 107.
46. Acuna-Castroviejo D, Coto-Montes A, Gaia Monti M et al. Melatonin is protective against MPTP-induced striatal and hippocampal lesions. Life Sci 1997 60 : PL23 PL29.
47. Jou MJ, Peng TI, Reiter RJ et al. Visualization of the antioxidative effects of melatonin at the mitochondrial level during oxidative stress-induced apoptosis of rat brain astrocytes. J Pineal Res 2004 37 : 55 70.
48. Kim YS, Joo WS, Jin BK et al. Melatonin protects 6-OHDA-induced neuronal death of nigrostriatal dopaminergic system. Neuroreport 1998 9 : 2387 2390.
49. Joo WS, Jin BK, Park CW et al. Melatonin increases striatal dopaminergic function in 6-OHDA-lesioned rats. Neuroreport 1998 9 : 4123 4126.
50. Mayo JC, Sainz RM, Uria H et al. Melatonin prevents apoptosis induced by 6-hydroxydopamine in neuronal cells: implications for Parkinson's disease. J Pineal Res 1998 24 : 179 192.
51. Dabbeni-Sala F, Di Santo S, Franceschini D et al. Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity. Faseb J 2001 15 : 164 170.
52. Jin BK, Shin DY, Jeong MY et al. Melatonin protects nigral dopaminergic neurons from 1-methyl-4-phenylpyridinium (MPP+) neurotoxicity in rats. Neurosci Lett 1998 245 : 61 64.
53. Ortiz GG, Crespo-Lopez ME, Moran-Moguel C et al. Protective role of melatonin against MPTP-induced mouse brain cell DNA fragmentation and apoptosis in vivo. Neuro Endocrinol Lett 2001 22 : 101 108.
54. Chen ST, Chuang JI, Hong MH et al. Melatonin attenuates MPP+-induced neurodegeneration and glutathione impairment in the nigrostriatal dopaminergic pathway. J Pineal Res 2002 32 : 262 269.
55. Khaldy H, Escames G, Leon J et al. Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion. Neurobiol Aging 2003 24 : 491 500.
56. Thomas B, Mohanakumar KP. Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 2004 36 : 25 32.
57. Coulom H, Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J Neurosci 2004 24 : 10993 10998.
58. Lezoualc'h F, Sparapani M, Behl C. N-acetyl-serotonin (normelatonin) and melatonin protect neurons against oxidative challenges and suppress the activity of the transcription factor NF-kappaB. J Pineal Res 1998 24 : 168 178.